Clear market notes built around the JSE, the rand, and what matters locally.

2026-08-07 22:35 • The Motley Fool Positive Axe Cap view: Selective

Fluor Corporation surged 16.92% on Friday after posting strong second-quarter earnings that beat analyst expectations. The company reported $4.3 billion in revenue (up 9% YoY) and adjusted net income of $0.91 per share (up 79% YoY), exceeding analyst estimates of $3.9 billion revenue and $0.70 EPS. New awards more than tripled to $6.1 billion from $1.8 billion year-over-year, demonstrating strong client confidence and business expansion.

Axe note: Fluor’s strong Q2 results pushed shares higher, though South African investors should be cautious given limited local linkage.

2026-08-07 22:30 • The Motley Fool Mixed Axe Cap view: Selective

Eli Lilly announced it will file for FDA approval of retatrutide, its next-generation weight-loss drug, in Q1 2027. The drug demonstrated 28.3% average weight loss over 80 weeks in phase 3 trials, outperforming competitors like Novo Nordisk's Wegovy. With strong Q2 financial results (48% revenue growth) and potential applications beyond obesity, Eli Lilly is positioned to expand its market lead.

Axe note: Eli Lilly’s retatrutide could shake up the obesity drug market, challenging Novo Nordisk’s dominance.

2026-08-07 22:27 • The Motley Fool Positive Axe Cap view: Selective

AtriCure director Maggie Yuen sold 3,500 shares (20% of her stake) at $38.42 per share on August 5, 2026, totaling $134,470. The sale occurred after the company reported strong Q2 results with 13% revenue growth to $154 million and expanded gross margins to 77%. The stock has surged over 60% since June lows, and analysts suggest the director sales likely reflect a post-earnings trading window opening rather than loss of confidence in the company.

Axe note: Director share sales at AtriCure reflect normal post-earnings activity, not a red flag.